Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The company has operations in Europe, Singapore, and the United States of America. The company develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.
Follow-Up Questions
Clinuvel Pharmaceuticals Ltd 的 CEO 是谁？
Dr. Philippe Wolgen 是 Clinuvel Pharmaceuticals Ltd 的 Chief Executive Officer，自 2005 加入公司。
CLVLF 股票的价格表现如何？
CLVLF 的当前价格为 $7.43，在上个交易日 decreased 了 0%。
Clinuvel Pharmaceuticals Ltd 的主要业务主题或行业是什么？
Clinuvel Pharmaceuticals Ltd 属于 Biotechnology 行业，该板块是 Health Care
